Verrica Pharmaceuticals Inc. Reports Q2 2026 Financial Results

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a clinical‑stage dermatology company, released its second‑quarter 2026 financial results on August 6, 2026. The company reported total revenue of $5.9 million, driven primarily by sales of its product YCANTH.

Revenue Highlights

  • Total revenue: $5.9 million (up 18.7 % sequentially, 12.3 % year‑over‑year).
  • U.S. YCANTH net product revenue: $5.1 million.
  • Dispensed applicator units: 19,626 units in Q2 2026, representing a 28.3 % increase from the prior quarter and a 46.1 % rise year‑over‑year.

These figures indicate sustained demand for YCANTH, positioning it as a potential standard of care for molluscum contagiosum.

Commercial and Development Progress

  • YCANTH’s commercial strategy continues to generate momentum; the company anticipates additional data from its global Phase 3 program on common warts by mid‑2027.
  • The first pivotal study, COVE‑2, and the second pivotal trial, COVE‑3, have enrolled patients in the United States and Japan.
  • In its basal cell carcinoma pipeline, Verrica’s oncolytic peptide VP‑315 demonstrated encouraging Phase 2 results, including a potential abscopal effect, and is moving toward Phase 3 readiness.

Capital Resources

On August 6, 2026, Verrica announced the approval of a $27.5 million credit facility controlled by Chairman Paul B. Manning. The facility is non‑dilutive and is expected to extend the company’s cash runway into 2028, assuming full utilization and continued operating performance.

Earnings Call

A conference call to discuss the results was scheduled for 4:30 p.m. ET on August 6, 2026. The call was accessible via toll‑free number 1‑800‑225‑9448 (domestic) or 1‑203‑518‑9708 (international).

Market Context

  • Close price (2026‑08‑04): $5.51
  • 52‑week high (2025‑11‑27): $9.821
  • 52‑week low (2025‑11‑03): $3.28
  • Market capitalization: $89.67 million
  • Price‑to‑earnings ratio: –4.15

The company’s financial performance, coupled with its expanding commercial footprint and access to additional capital, underscores its strategy to accelerate the commercialization of YCANTH while advancing pipeline assets.